A house exploded Tuesday morning in the Bronx killing a FDNY battalion chief and injuring at least 12 people, according to a NBC New York report.
Former FDA Deputy Commissioner Scott Gottlieb, M.D. weighs in on Mylan's pricing outrage and what's really driving drug price hikes.
Philippine President Rodrigo Duterte invited UN Secretary-General Ban Ki-moon and the European Union to investigate his anti-drugs crackdown.
Sarepta soars on FDA approval. Stephen Weiss, Short Hills Captial, discusses how investors should approach the name.
Wells Fargo's $185 million settlement, and Mylan's EpiPen mess were about corporate greed, the Aspen Institute CEO says.
A serious warning on Pfizer's quit smoking drug should be removed, panelists to the U.S. Food and Drug Administration recommended on Wednesday.
David Maris, Wells Fargo Securities, and CNBC's Meg Tirrell talk about rebates, the outrage over drug prices and Hillary Clinton's drug price plan.
CNBC's Meg Tirrell reports on how Hillary Clinton's policies on drug pricing will impact the industry and investors.
CNBC's John Harwood reports on Hillary Clinton's new plan aimed to tackle drug price hikes.
Mylan's EpiPen price hike is just the latest in a series of "poor management" decisions by the board, NYC Comptroller Scott Stringer tells CNBC.
The Philippine President will be meeting Barack Obama in Laos next week on the sidelines of an East Asia summit.
Opioids now kill more people than auto accidents or guns. What can be done to curb this epidemic, with U.S. Surgeon General Vivek Murthy.
The only way to stop drug companies from jacking up the costs of live-saving treatments is through price controls, a former Obama health advisor says.
Chief pharmacy officer at the Cleveland Clinic discusses Mylan's "generic" version of its own product, the Epipen, on CNBC's "Closing Bell."
CNBC's Meg Tirrell reports on Mylan's decision to launch a generic EpiPen as a way of cutting the cost of the treatment.
Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC.
Bill Ackman tells CNBC the past 12 months were the "worst period of performance" of his career, and the implosion of Valeant Pharmaceuticals was mostly to blame.
CNBC’s Meg Tirrell reports the latest on Mylan prices and the drug price blame game.
Chris Kofinis, a Democratic strategist - who worked for Mylan CEO Heather Bresch's father, Sen. Joe Manchin - criticizes her response to the EpiPen "crisis."